J&J: DCF Signals 8% Upside for Healthcare Behemoth
By stockpickr AI | March 3, 2026 | 10 min read
Investment Summary
Based on a Discounted Cash Flow (DCF) analysis, Johnson & Johnson (Healthcare) appears slightly undervalued relative to its intrinsic value calculation.
Investment Recommendation
Buy
Fair Value: $162.50
Current Price: $149.94
Upside/Downside: +8.38%
The DCF valuation indicates an implied fair value slightly exceeding the current market price of $149.94, suggesting a modest upside potential. This recommendation is driven primarily by conservative long-term Free Cash Flow assumptions underpinned by stable pharmaceutical revenue streams.
Key Metrics
- Market Cap: $377.75B
- P/E Ratio: 21.40x
- Forward P/E: 14.15x
- Revenue Growth (YoY): 2.3%
- Net Margin: 17.5%
- ROE: 23.10%
- Debt/Equity: 0.35
- Dividend Yield: 3.10%
Strengths
- Strong financial stability with a trailing twelve-month revenue exceeding $85.15B.
- Significant operational efficiency reflected in a Net Margin of 17.5%.
- Defensive characteristics in the Healthcare sector, providing resilience during economic downturns.
- Commitment to shareholder returns, marked by over 60 consecutive years of dividend increases.
Risk Factors
- Ongoing litigation risks, particularly related to talc products, although costs appear manageable.
- Pressure on pricing and patent cliffs for key high-revenue pharmaceutical products.
- Integration complexities following the spin-off of the Consumer Health division (Kenvue).